标靶蛋白降解（TPD）市场规模、份额及成长分析（按类型、治疗领域、给药途径、最终用途及地区划分）－2026-2033年产业预测

全球标靶蛋白质降解市场规模预计在 2024 年达到 6.4602 亿美元，从 2025 年的 8.2626 亿美元增长到 2033 年的 59.1674 亿美元，在预测期（2026-2033 年）内复合年增长率为 27.9%。

全球标靶蛋白降解市场正日益受到关注，它是一种创新的药物研发策略，利用小分子化合物特异性清除疾病相关蛋白。该方法的关键优势在于其广泛的适用性，能够治疗多种传统上“难治性疾病”，包括某些癌症和遗传性疾病。标靶蛋白降解的选择性可最大限度地减少脱靶效应，从而提高疗效并降低副作用。此外，该疗法的持久性也得到提升，其疗效持续时间比传统药物更长，从而减少了给药频率，提高了患者的依从性。这种全新的作用机制为联合治疗开启了可能性，进一步拓展了治疗选择，并推动了标靶蛋白降解市场的成长。

全球标靶蛋白降解市场驱动因素

全球标靶蛋白降解市场正经历显着成长，这主要得益于人们对更有效疾病治疗方案的需求不断增长。癌症、遗传性疾病和自体免疫疾病等病症对患者健康造成重大影响，凸显了针对这些疾病根本原因的治疗方法的紧迫性。标靶蛋白降解技术可望选择性地降解疾病相关蛋白，在提高疗效的同时减少副作用。这种创新方法能够开发出针对有害蛋白质且不损伤健康细胞的药物，从而在改善患者预后的同时最大限度地减少不良反应。此外，这种标靶机制为以往被认为「无法治癒」的疑难杂症提供了解决方案，开闢了药物研发的新途径，并为治疗选择有限的患者带来了新的希望。

抑制全球标靶蛋白质降解市场

由于靶向蛋白降解领域固有的复杂性，该市场面临巨大的挑战。这种创新方法需要对蛋白质结构和功能有深入的了解，以及先进的药物设计和开发技术。围绕靶向蛋白降解开发新治疗方法的过程通常复杂且漫长，这可能会减缓该领域的进展。开发人员必须透彻理解疾病的生物机制和所涉及的特定蛋白质，才能创造出有效的解决方案。此外，设计能够与细胞降解机制相互作用的高效、选择性强且稳定的分子至关重要，这需要大量的研发投入。

全球标靶蛋白降解市场趋势

全球标靶蛋白降解市场正呈现显着的趋势，即开发口服药物製剂，这主要得益于患者对更便捷治疗方法日益增长的需求。这些口服疗法具有无与伦比的便利性，使患者无需频繁就医或接受侵入性治疗即可有效控制病情。药厂正优先研发能够有效透过消化器官系统并利用缓释机制维持疗效的口服药物。这项转变有望透过提供更易于管理且更便捷的治疗方案来改善患者照护，并提高患者的依从性，而这对于治疗的成功至关重要。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析

全球标靶蛋白降解（TPD）市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 地塞米胺
• 免疫调节药物（IMIDS）
• 蛋白水解靶向嵌合体分子（PROTACS）
• 突发性视网膜退化症候群（SARDS）
• 选择性雌激素受体降解剂（SERDS）
• 其他的

全球标靶蛋白降解（TPD）市场规模（依治疗领域划分）及复合年增长率（2026-2033 年）

• 发炎性疾病
• 神经系统疾病
• 肿瘤疾病
• 呼吸系统疾病
• 其他的

全球标靶蛋白降解（TPD）市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 口服
• 静脉注射
• 其他的

全球标靶蛋白降解 (TPD) 市场规模（按最终用途和复合年增长率划分）（2026-2033 年）

• 製药和生物技术公司
• 学术和研究机构
• 医院和临床检查室
• 其他的

全球标靶蛋白降解（TPD）市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
• 2023-2025年营收年比比较

主要企业简介

• Arvinas（USA）
• Kymera Therapeutics（USA）
• Nurix Therapeutics（USA）
• C4 Therapeutics（USA）
• Foghorn Therapeutics（USA）
• Zymeworks（Canada）
• Bristol-Myers Squibb（USA）
• Pfizer（USA）
• AbbVie（USA）
• Sanofi（France）
• Roche（Switzerland）
• AstraZeneca（UK）
• Vertex Pharmaceuticals（USA）
• Amgen（USA）
• Takeda Pharmaceutical（Japan）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Merck & Co.（USA）
• Janssen Pharmaceuticals（Johnson & Johnson）（USA）
• BeiGene（China）

结论与建议

Global Targeted Protein Degradation Market size was valued at USD 646.02 Million in 2024 and is poised to grow from USD 826.26 Million in 2025 to USD 5916.74 Million by 2033, growing at a CAGR of 27.9% during the forecast period (2026-2033).

The market for Global Targeted Protein Degradation is gaining traction as an innovative drug development strategy that employs small molecules to specifically eliminate disease-related proteins. Key benefits of this approach include its broad applicability, allowing treatment of various conditions previously deemed "undruggable," such as certain cancers and genetic disorders. The selectivity offered by targeted protein degradation minimizes off-target effects, enhancing the therapeutic impact while reducing side effects. Additionally, treatments can demonstrate increased durability, maintaining efficacy longer than conventional drugs, which may lead to less frequent dosing and improved patient adherence. This novel mode of action paves the way for combination therapies, further broadening the therapeutic landscape and driving growth within the targeted protein degradation market segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Protein Degradation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Protein Degradation Market Segments Analysis

Global Targeted Protein Degradation Market is segmented by type, therapeutic area, route of administration, end use and region. Based on type, the market is segmented into degronimids, immunomodulatory drugs (IMIDS), proteolysis-targeting chimeric molecules (PROTACS), sudden acquired retinal degeneration syndrome (SARDS), selective estrogen receptor degraders (SERDS) and others. Based on therapeutic area, the market is segmented into inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders and others. Based on route of administration, the market is segmented into oral, intravenous and others. Based on end use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & clinical laboratories and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Protein Degradation Market

The Global Targeted Protein Degradation market is experiencing considerable growth driven by the increasing demand for more effective therapeutic options across various diseases. Conditions such as cancer, genetic disorders, and autoimmune disorders significantly affect patient well-being, highlighting the urgent need for treatments that target the root causes of these illnesses. Targeted protein degradation technology holds promise in selectively degrading disease-related proteins, thereby offering improved treatment efficacy with potentially fewer side effects. This innovative approach facilitates the creation of drugs that focus on harmful proteins while leaving healthy cells intact, minimizing adverse reactions and enhancing patient outcomes. Furthermore, this targeted mechanism presents solutions for challenging diseases previously deemed "undruggable," unlocking new avenues for drug development and providing renewed hope for patients with limited treatment options.

Restraints in the Global Targeted Protein Degradation Market

The targeted protein degradation market encounters significant challenges due to the inherent complexity of the field. This innovative approach necessitates an in-depth comprehension of protein structure and function, along with sophisticated drug design and development skills. The process of creating new therapies centered on targeted protein degradation is often intricate and lengthy, causing potential delays in advancements within the sector. Developers must thoroughly understand disease biology and the specific proteins involved to craft effective solutions. Additionally, the design of potent, selective, and stable molecules that can interact with the cellular degradation machinery is essential, demanding substantial investment in research and development.

Market Trends of the Global Targeted Protein Degradation Market

The Global Targeted Protein Degradation market is witnessing a significant trend towards the development of oral drug formulations, driven by the increasing demand for more patient-friendly treatment options. These oral therapies offer unparalleled convenience, allowing patients to manage their conditions without the need for frequent clinic visits or invasive procedures. Pharmaceutical companies are prioritizing research to create oral drugs that can effectively navigate the digestive system and maintain therapeutic efficacy through sustained release mechanisms. This shift not only enhances patient compliance, vital for treatment success, but also promises to transform patient care by facilitating more manageable and accessible therapeutic options for a variety of diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Targeted Protein Degradation Market Size by Type & CAGR (2026-2033)

• Market Overview
• Degronimids
• Immunomodulatory Drugs (IMIDS)
• Proteolysis-Targeting Chimeric Molecules (PROTACS)
• Sudden Acquired Retinal Degeneration Syndrome (SARDS)
• Selective Estrogen Receptor Degraders (SERDS)
• Others

Global Targeted Protein Degradation Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Inflammatory Disorders
• Neurological Disorders
• Oncological Disorders
• Respiratory Disorders
• Others

Global Targeted Protein Degradation Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Others

Global Targeted Protein Degradation Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Clinical Laboratories
• Others

Global Targeted Protein Degradation Market Size & CAGR (2026-2033)

• North America (Type, Therapeutic Area, Route of Administration, End Use)
  • US
  • Canada
• Europe (Type, Therapeutic Area, Route of Administration, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, Route of Administration, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, Route of Administration, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, Route of Administration, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Arvinas (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foghorn Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations